FDA Commissioner: No ‘Preconceived Plans’ on Policy Changes for Abortion Drug

FDA Head to ‘Listen to Concerns’ Regarding Coerced Use of Abortion Pill Widely Available Online

Open the article to view the coverage from The Georgia Star News

FDA chief has no 'plans' for abortion pill policy changes but continues safety review

FDA's Makary commits to reviewing abortion pill mifepristone safety data while listening to concerns, stating he has no plans for policy changes.

FDA commissioner: No ‘preconceived plans’ on policy changes for abortion drug

AAF Urges FDA for Transparency on Mifepristone for Women’s Safety - Advancing American Freedom

Advancing American Freedom applauds FDA Director Makary for pledging to review the safety and efficacy of mifepristone. For too long, women’s health has been sacrificed for vested interests and political gains. American women deserve an honest reassessment of mifepristone and the REMS essential to protecting women that have been increasingly stripped by Democratic Administrations, especially when the Ethics and Public Policy Center’s study of in…

FDA chief has no 'plans' for abortion pill policy changes but continues safety review – Democratic Accent

Food and Drug Administration Commissioner Marty Makary said in a recent interview he has “no preconceived plans” to modify policies surrounding abortion pill mifepristone, which is designed to end a pregnancy in the first 10 weeks. “We have an ongoing review of safety data on mifepristone, which is a requirement from the prior administrations,” Makary said in an interview with POLITICO. “You always have to be open-minded. You have to listen to d…